FDA Approves First Therapy for Allergic Fungal Rhinosinusitis - Takeaways - MDSpire

FDA Approves First Therapy for Allergic Fungal Rhinosinusitis

Patients with allergic fungal rhinosinusitis now have a targeted biologic option.

Share

1

Dupilumab is the first FDA-approved therapy for allergic fungal rhinosinusitis in patients aged 6 years and older.
2

The condition affects up to 8% of patients with chronic sinus inflammation and is characterized by thick mucus accumulation.
3

Dupilumab treatment improved sinus opacification, nasal polyp size, nasal congestion, and olfactory function over 52 weeks.
4

The therapy reduced the need for systemic corticosteroids and sinus surgery, and decreased sinus bone erosion.
5

Common adverse reactions to dupilumab include injection-site reactions, eosinophilia, insomnia, and toothache.